The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Prevalence and Trends of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease among Adults in the United States

Authors: Zhengxi Chen, MS, Holly Hartman, PhD, Abhishek Deshpande, MD, PhD

Abstract

Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 100 million individuals in the United States. Previous studies have reported a significant association between obesity and MASLD. The objective of our study was to examine the relationship between obesity and population-level trends in MASLD prevalence among US adults aged 20 years and older.

Methods: We conducted a retrospective analysis of serial cross-sectional data from the National Health and Nutrition Examination Survey cycles (1999–2018). MASLD was defined using two criteria: (1) US Fatty Liver Index (USFLI) ≥30 or (2) cardiometabolic risk factors (≥1) with controlled attenuation parameter ≥288 dB/m (2017–2018 only). Temporal trends in the prevalence of MASLD and obesity were analyzed using logistic regression with the midpoint of a 2-year survey cycle as a continuous independent variable. Adjusted odds ratios (ORs) quantified obesity’s association with MASLD trends, controlling for age, sex, race/ethnicity, and survey design variables.

Results: Among 17,824 participants, 36.62% were obese (body mass index ≥30 kg/m2) and 33.49% met MASLD criteria (USFLI ≥30). MASLD prevalence increased from 30.20% (95% confidence interval [CI] 26.57%–33.83%) in 1999–2000 to 38.64% (95% CI 35.47%–41.80%) in 2017–2018 mirroring rising obesity rates (30.26%–43.51%). MASLD prevalence varied significantly across different demographics, with the highest rates observed in older adults, males, and Mexican Americans. Obesity was associated with a 14.05-fold higher odds of MASLD (95% CI 12.62–15.65).

Conclusions: MASLD prevalence trends closely parallel the obesity epidemic, with obesity strongly associated with MASLD risk. The differential prevalence rates among older adults, males, and Mexican Americans highlight the need for targeted prevention strategies, including obesity management.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol 2014;13:166–178.
 
2. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight—reconsidering the use of race correction in clinical algorithms. N Engl J Med 2020;383:874–882.
 
3. Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol 2017;9:715–732.
 
4. Noureddin M, Ntanios F, Malhotra D, et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning. Hepatol Commun 2022;6:1537–1548.
 
5. Hagstrom H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2024;80:e76–e77.
 
6. Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology 2024;79:666–673.
 
7. Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564–568.
 
8. Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022;22:63.
 
9. Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One 2017;12:e0173499.
 
10. Wang J, Xia P, Ma M, et al. Trends in the prevalence of metabolically healthy obesity among US adults, 1999-2018. JAMA Netw Open 2023;6:e232145.
 
11. Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016;315:2284–2291.
 
12. Temple NJ. The origins of the obesity epidemic in the USA—lessons for today. Nutrients 2022;14:4253. .
 
13. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015;41:65–76.
 
14. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (London) 2018;18:245–250.
 
15. Cheng HY, Wang HY, Chang WH, et al. Nonalcoholic fatty liver disease: prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance. Int J Gerontol 2013;7:194–198. .
 
16. Riazi K, Swain MG, Congly SE, et al. Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review. Nutrients 2022;14:4556.
 
17. Samji NS, Snell PD, Singal AK, et al. Racial disparities in diagnosis and prognosis of nonalcoholic fatty liver disease. Clin Liver Dis 2020;16:66–72.
 
18. Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J Obes Metab Syndr 2022;31:17–27.
 
19. Vassilopoulos A, Kalligeros M, Vassilopoulos S, et al. Prevalence of steatotic liver disease among US adults with rheumatoid arthritis. Dig Dis Sci 2024;69:989–1003.
 
20. Kalligeros M, Vassilopoulos A, Vassilopoulos S, et al. Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020. Clin Gastroenterol Hepatol 2024;22:1330–1332.e4.
 
21. Pfeiffer CM, Sternberg MR, Schleicher RL, et al. The CDC’s Second National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population is a valuable tool for researchers and policy makers. J Nutr 2013;143:938S–947S.
 
22. Mazidi M, Katsiki N, Mikhailidis DP, et al. Ideal cardiovascular health associated with fatty liver: results from a multi-ethnic survey. Atherosclerosis 2019;284:129–135.
 
23. Nguyen VK, Middleton LYM, Huang L, et al. Harmonized US National Health and Nutrition Examination Survey 1988-2018 for high throughput exposome–health discovery. medRxiv 2023;2023.02.06.23284573.
 
24. Liu B, Du Y, Wu Y, et al. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ 2021;372:n365.
 
25. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) anthropometry procedures manual. https://wwwn.cdc.gov/nchs/data/nhanes/public/2021/manuals/2021-Anthropometry-Procedures-Manual-508.pdf. Published May 2021. Accessed Feb 2025.
 
26. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) MEC laboratory procedures manual. https://wwwn.cdc.gov/nchs/data/nhanes/public/2021/manuals/2021-Laboratory-Procedures-508.pdf. Published February 2022. Accessed February 10, 2025.
 
27. Le MH, Yeo YH, Cheung R, et al. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711–722.
 
28. Centers for Disease Control and Prevention, National Center for Health Statistics. An investigation of nonresponse bias and sample characteristics in the 2017 − 2018 National Health and Nutrition Examination Survey. https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/17-18-sampling-variability-nonresponse-508.pdf. Published 2020. Accessed October 28, 2025.
 
29. National Center for Health Statistics. National Health and Nutrition Examination Survey: analytic guidelines, 2011-2014 and 2015-2016. https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/11-16-analytic-guidelines.pdf. Published December 14, 2018. Accessed October 28, 2025.
 
30. Zhang X, Heredia NI, Balakrishnan M, et al. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017-2018. PLoS One 2021;16:e0252164.
 
31. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.
 
32. Shen TH, Wu CH, Lee YW, et al. Prevalence, trends, and characteristics of nonalcoholic fatty liver disease among the US population aged 12–79 years. Eur J Gastroenterol Hepatol 2024;36:636–645.
 
33. Centers for Disease Control and Prevention, National Center for Health Statistics. NHANES response rates and population totals. https://wwwn.cdc.gov/nchs/nhanes/ResponseRates.aspx. Accessed August 4, 2020.
 
34. Jih J, Mukherjea A, Vittinghoff E, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med 2014;65:1–6.